» Articles » PMID: 26460959

The Double Face of Morgana in Tumorigenesis

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Oct 14
PMID 26460959
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Morgana is a chaperone protein able to bind to ROCK I and II and to inhibit their kinase activity. Rho kinases are multifunctional proteins involved in different cellular processes, including cytoskeleton organization, centrosome duplication, cell survival and proliferation. In human cancer samples Morgana appears to be either downregulated or overexpressed, and experimental evidence indicate that Morgana behaves both as an oncosuppressor and as a proto-oncogene. Our most recent findings demonstrated that if on the one hand low Morgana expression levels, by inducing ROCK II hyperactivation, cause centrosome overduplication and genomic instability, on the other hand, Morgana overexpression induces tumor cell survival and chemoresistance through the ROCK I-PTEN-AKT axis. Therefore, Morgana belongs to a new class of proteins, displaying both oncogenic and oncosuppressor features, depending on the specific cellular context.

Citing Articles

miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia.

Poggio P, Rocca S, Fusella F, Ferretti R, Ala U, DAnna F Sci Rep. 2024; 14(1):15089.

PMID: 38956394 PMC: 11220062. DOI: 10.1038/s41598-024-65404-7.


Morgana is an Hsp90-interacting protein with a direct role in microtubule polymerisation.

Palumbo V, Tariq A, Borgal L, Metz J, Brancaccio M, Gatti M J Cell Sci. 2020; 133(2).

PMID: 31907206 PMC: 6983718. DOI: 10.1242/jcs.236786.


The one thousand and one chaperones of the NF-κB pathway.

Fusella F, Secli L, Cannata C, Brancaccio M Cell Mol Life Sci. 2019; 77(12):2275-2288.

PMID: 31811308 PMC: 11104964. DOI: 10.1007/s00018-019-03402-z.


Escaping NK cells and recruiting neutrophils: How Morgana/NF-κB signaling promotes metastasis.

Fusella F, Secli L, Brancaccio M Mol Cell Oncol. 2018; 5(3):e1432258.

PMID: 30250889 PMC: 6150045. DOI: 10.1080/23723556.2018.1432258.


Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.

Rocca S, Carra G, Poggio P, Morotti A, Brancaccio M Mol Cancer. 2018; 17(1):40.

PMID: 29455651 PMC: 5817721. DOI: 10.1186/s12943-018-0774-4.


References
1.
Gerstner J, Landry C . The zinc-binding protein chordc1 undergoes complex diurnal changes in mRNA expression during mouse brain development. Neurochem Res. 2007; 32(2):241-50. PMC: 6528676. DOI: 10.1007/s11064-006-9271-z. View

2.
Garcia-Ranea J, Mirey G, Camonis J, Valencia A . p23 and HSP20/alpha-crystallin proteins define a conserved sequence domain present in other eukaryotic protein families. FEBS Lett. 2002; 529(2-3):162-7. DOI: 10.1016/s0014-5793(02)03321-5. View

3.
Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C . Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009; 15(2):441-51. DOI: 10.1158/1078-0432.CCR-08-1791. View

4.
Lochhead P, Wickman G, Mezna M, Olson M . Activating ROCK1 somatic mutations in human cancer. Oncogene. 2010; 29(17):2591-8. DOI: 10.1038/onc.2010.3. View

5.
Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View